Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system

BACKGROUND: Amikacin inhale (BAY41-6551), a unique drug—device combination of a specially formulated drug solution and a pulmonary drug delivery system device (AMK-I) is currently under phase III study as an adjunctive therapy to IV antibiotics for the treatment of Gram-negative pneumonia in mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazi, Islam M., Grupper, Mordechai, Nicolau, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240302/
https://www.ncbi.nlm.nih.gov/pubmed/28095918
http://dx.doi.org/10.1186/s12941-017-0178-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240302/
https://www.ncbi.nlm.nih.gov/pubmed/28095918
http://dx.doi.org/10.1186/s12941-017-0178-0

Ejemplares similares